Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers

Journal of Clinical Pharmacology

Volumn 36, Issue 3, 1996, Pages 216-229

  Patat, Alain ^a,b   Le Coz, Franck ^b   Dubruc, Catherine ^a   Gandon, Jean Marc ^b   Durrieu, Geneviève ^a   Cimarosti, Isabelle ^b   Jezequel, Sylvie ^a   Curet, Olivier ^a   Zieleniuk, Isabelle ^a   Allain, Hervé ^c   Rosenzweig, Pierre ^a  

^a SANOFI   (France)

^b Biotrial SA   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; AMINE OXIDASE (FLAVIN CONTAINING); BEFLOXATONE; MONOAMINE OXIDASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; MALE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 9244260501     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04191.x     Document Type: Article

References (42)

1. Pare CMB: The present status of monoamine oxidase inhibitors. Br J Psychiatry 1985;146:576-584.
2. Murphy DL, Aulakh CS, Garrick NA, Sunderland T: Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In, Meltzer HY (ed.): Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987;545-552.
3. Martin L, Bakish D, Joffer R: MAO inhibitor treatment of depression. In, Kennedy SH (ed.): Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington. DC: American Psychiatric Press, 1994;147-180.
4. Quitkin FM, Rothschild R, Stewart JW, McGrath PJ, Harrison WM: Atypical depression: a unipolor depressive subtype with preferential response to MAO inhibitors (Columbia University depressive studies). In, Kennedy SH (ed.): Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington, DC: American Psychiatric Press, 1994;181-203.
5. Blackwell B, Marley E, Price J, Taylor D: Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-365-
6. Marley E, Blackwell B: Interactions of monoamine oxidase inhibitors, amines and foodstuffs. Adv Pharmacol Chemother 1970;8:185-239.
7. Fitton A, Faulds D, Goa L: Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-596.
8. Möller HJ, Wendt G, Waldmeier P: Brofaromine, a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings. Pharmacopsychiatry 1991;24: 50-54.
9. Rovei V, Caille D, Curet O, Ego D, Jarreau FX: Biochemical pharmacology of befloxatone (MD 370503), a new potent reversible MAO-A inhibitor J Neural Transm 1994;41:339-347.
10. Rovei V, Benavides J, Caille D, Curet O, Depoortere M, Ego D, Patat A, Scatton B: Biochemical pharmacology of befloxatone, a reversible selective and competitive inhibitor of MAO-A (abstract). Neuropsychopharmacology 1994; 10:3055.
11. Bieck PR, Antonin KH: Tyramine potentiation during treatment with MAO inhibitors. In, Kennedy SH (ed.): Progress in Psychiatry, Volume 43: Clinical Advances in Monoamine Oxidase Inhibitor Therapies. Washington, DC: American Psychiatric Press, 1994;83-110.
12. Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P. Caille P: Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995;35:633-643.
13. Ghose K: Assessment of peripheral adrenergic activity and its interaction with drugs in man. Eur J Clin Pharmacol 1980;17:233-238.
14. Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D: Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacotogy 1993;112(suppl):S76-S84.
15. Sandler M, Youdim MBH: Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev 1972;24:331-348.
16. Jackman G, Snell J, Skews H, Bobik A: Effects of noradrenergic neuronal activity on 3,4-dihydroxyphenylglycol levels: quantitation by liquid chromatography. Life Sci 1982;3:923-929.
17. Robinson DS, Johnson GA, Nies A, Carcella J, Couper TB, Albright D, Howard D: Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J Clin Pharmacol 1983;23:282-287.
18. Graefe KH, Henseling M: Neuronal and extraneuronal uptake and metabolism of catecholamies. Gen Pharmacol 1983;14:27-33.
19. Izzo JL, Thompson DA, Horwitz D: Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism. Life Sci 1985;37:1033-1038.
20. Halbrugge T, Gerhardt T, Ludwig J, Heidbreder E, Graefe KH: Assay of catecholamines and dihydroxyphenylethyleneglycol in human plasma and its application in orthostasis and mental stress. Life Sci 1988;43:19-26.
21. Goldstein DS, Eisenhofer G, Stull R, Folin CJ, Keiser HR, Kopin IJ: Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest 1988;81:213-220.
22. Warsh JJ, Godse DD, Cheung SW, Li PP: Rat brain and plasma norepinephrine glycol metabolites determined by gas chromatography-mass fragmentography. J Neurochem 1981;36:893-901.
23. Scatton B: Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity. Life Sci 1982;31:495-504.
24. Dennis T, Benkelfat C, Touitou Y, Auzeby A, Poirier MF, Scatton B, Loo H: Lack of circadian rhythm in plasma levels of 3,4-dihydroxyphenylethyleneglycol in healthy human subjects. Psychophormacology 1986;90:471-474.
25. Brown MJ, Monks NJ: Plasma dihydroxyphenylglycol concentration: a simple, sensitive and specific index of monoamine oxidase-A activity in vivo (abstract). Br J Clin Pharmacol 1983;15: 599P.
26. Koulu M, Scheinin M, Kaartinen A, Kallio J, Pyykko K, Vuorinen J, Zimmer RH: Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-255.
27. Scheinin VI, Karhuvaara S, Ojala-Karlson P, Kallio A, Koulu M: Plasma 3, 4-dihydroxyphenylglycol (DHPG) are insensitive indicators of α-2-adrenoreceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci 1990;49: 75-84.
28. Curet O, Damoiseau G, Labaune JP, Rovei V, Jarreau FX: Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J Neural Tronsm 1994;41:349-355.
29. Ansseau M, Caille P, Derks C, Cieren-Puiseux I, Wauthy J, Ego D, et al: Phase I study of single ascending doses of befloxatone. a new reversible MAO-A inhibitor antidepressant (abstract). Clin Neuropharmacol 1992;15(suppl):328B.
30. Patat A, Gandon JM, Durrieu G, Raoul P, le Coz F, Beck A, et al: Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects. Hum Psychopharmacol 1995;10:110-125.
31. Eisenhofer G, Goldstem DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ: Simultaneous liquid-chromatographic determination of 3, 4-dihydroxyphenylglycol, catecholamines, and 3, 4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030-2033.
32. Brown MJ, Monks NJ: Plasma dihydroxyphenylglycol concentration: a simple, sensitive and specific index of monoamine oxidase-A activity in man. In. Tipton KF, Dostert P, Benedetti MS (eds.): Mononmine Oxidase and Disease. London. Academic Press 1984:559-560.
33. Dingemanse J, Korne A, Pfefen JP, Guntert TW: Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology 1992;106:S46-S48.
34. Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ: Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase. Psychopharmacology 1992;106(suppl): S68-S70.
35. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 1990;30:805-816.
36. Gasic S, Korn A, Eichler HG, Oberhummer I, Zapotocky HG: Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 1983;25:173-177.
37. Korn A, da Prada M, Raffesberg W, Allen S, Gasic S, Eichler HG: Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 1988;11:17-23.
38. Korn A, da Prada M, Raffesberg W, Allen S, Gasic S: Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1988; 26(Suppl):57-71.
39. Cusson JR, Goldenberg E, Larochelle P: Effect of a novel monoamine-oxidase inhibitor, moclobemide, on the sensitivity to intravenous tyramine and norepinephrine in humans. J Clin Pharmacol 1991;31:462-467.
40. Holford NHG, Guentert TW, Dingemanse J, Banken L: Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol 1994;37: 433-439.
41. Jusko WJ, Ko HC: Physiologic indirect response models characterize diverse type of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-419.
42. McDaniel K: Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986;9:207-234.